Mandate

Vinge advises Embellence Group AB (publ) in connection with the listing on Nasdaq First North Premier Growth Market

Vinge advises Embellence Group AB (publ) (“Embellence Group”) in connection with the listing on Nasdaq First North Premier Growth Market. The offering circular was published on 15 March 2021 and first day of trading was on 24 March 2021.

The offering price was SEK 42, corresponding to a market value of Embellence Group of approximately SEK 900 million. The offering comprised approximately 10.8 million shares, corresponding to a value of approximately SEK 454 million, provided that the overallotment option is exercised in its entirety.

Embellence Group, founded in 1905 in Borås, Sweden, is a leding European company in interior decoration, with a focus on premium brands within wallpaper, textile, rugs and other interior decoration with sales in over 90 countries. The company’s brand portfolio includes Cole & Son, Wall&decò, Perswall, Pappelina and Boråstapeter.

Vinge’s team mainly consisted of Johan Winnerblad, Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Linnea Petersson and Louise Brorsson Salomon, Pauline Lagerstrand and Rebecka Målquist regarding financing matters and Mattias Schömer and Henrik Wastenson regarding tax matters.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026